摘要
目的探讨应用伊马替尼(格列卫)治疗慢性粒细胞白血病发生严重水潴留的处理及其可能的发生机制。方法报道1例在应用格列卫治疗慢性粒细胞白血病加速期患者的过程中,发生严重全身水肿、胸腹腔积液的处理过程及经验,结合文献对其发生的可能机制进行综述。结果在用格列卫治疗慢粒的各阶段均有少数患者可能发生严重的水肿和体液潴留的不良反应,但在急变期和高龄患者较多见,若不及时处理有可能危及生命,需高度重视。格列卫引起严重水肿的机制目前认为与其抑制PDGF受体的活性相关。结论在应用格列卫治疗慢粒时应警惕该类不良反应的发生,一旦出现需及时对症处理并严密观察,必要时停药,待症状消失后再开始用药是安全的。
Objective To study the treatment and its possible mechanism of imatinib-induced severe fluid retention in chromic myeloid leukemia（CML）. Methods The treatment process for severe anasarca, hydrothorax and seroperitoneum of a CML accelerated phase patient getting imatinib therapy was represented,and the possible mechanism was reviewed. Results A few CML patients treated with imatinib could get severe edema and fluid retention in any phases of the treatment, especially for the aged patients or their illness were in accelerated phases. The above symptoms needed emergency treatment should be paid much attention to. The mechanism of imatinib-induced severe edema was thought to be associated with inhibition of PDGF receptor＇s activation. Conclusion The above side effects should be seriously cared during the CML treatment with imatinib,the treatments for the symptoms and the close observation should be applied in time. If needed, withdraw the imatinib treatment until the symptoms are disap- peared.
出处
《重庆医学》
CAS
CSCD
2007年第17期1720-1721,共2页
Chongqing medicine
基金
重庆市医学重点学科建设基金资助项目(2006C028)
